Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-26
2006-09-26
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S185000, C514S359000, C514S374000, C514S377000, C546S271400, C546S268100, C546S268400, C548S233000, C548S215000
Reexamination Certificate
active
07112599
ABSTRACT:
The present invention relates to compounds of the Formulawherein R3, R5, R6, R7, and Z, and other variables enumerated under one or more of R3, R5, R6, R7, and Z, are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
REFERENCES:
patent: 5821262 (1998-10-01), Crimmin et al.
patent: 6169102 (2001-01-01), Kanamaru et al.
patent: 6414003 (2002-07-01), Kanamaru et al.
patent: 6495548 (2002-12-01), Duan
patent: 2002/0002199 (2002-01-01), Jeppesen et al.
Gommaa, A.M., et al., “Synthesis and Biological Activity of Some New Submitted 2-(aminoacyl) Aminobenzoxazoles and Dipeptide Derivatives,” Asian J. Chemistry, col. 4, pp. 629-633 (Jul. 1992), especially at Table 1, cmpds XLVI-XLIX, XLI-XLII.
Nicolaides, E., et al., “Potential Agents. Carbobenzoxy Di- and Tripeptides Active Against Measles and Herpes Viruses,” J. Med. Chem., vol. 11(1), pp. 4-79 (Jan. 1968), especially at Table III, p. 78, line 39.
Stanley Prusiner, “Shattuck Lecture—Neurodegenerative Diseases and Prions,” N. Engl. J. Med., vol. 334(20), pp. 1516-1526 (May 21, 2001), at Table 2, p. 1518.
Cummings, Jeffrey L., “Alzheimer's Disease,” N. Engl. J. Med., vol. 351, pp. 56-67 (Jul. 1, 2004), at pp. 56-60.
Robinson, Stephen R., et al., “Lessons from the AN 1792 Alzheimer vaccine: lest we forget,” Neurobiol. of Aging, vol. 25(5), pp. 609-615 (May-Jun. 2004) at pp. 609-610.
Bullock, Roger, “Future directions in the treatment of Alzheimer's disease,” Expert Opin. Invest. Drugs, vol. 13(4), pp. 303-314 (2004), at pp. 303, 306-309.
Gommaa, A.M., et al., “Synthesis and Biological Activity of Some New Submitted 2-(aminoacyl) Aminobenzoxazoles and Dipeptide Derivatives,” Asian J. Chemistry, vol. 4(3), pp. 629-633 (Jul. 1992), at Table 1 insert, compounds XLVI-XLIX, XLI and XLII.
Nicolaides, E., et al., “Potential Agents. Carbobenzoxy Di- and Tripeptides Active Against Measles and Herpes Viruses,” J. Med. Chem., vol. 11(1), pp. 4-79 (Jan. 1968), especially at Table III, p. 78, line 39.
Compston, A., and Coles, A., “Multiple sclerosis,” The Lancet, vol. 359, pp. 1221-1231 (Apr. 6, 2002), at p. 1224, col. 2, lines 21 et seq.; p. 1226, line 10 et seq.; and p. 1221, lines 18-36.
Hartung, H., et al., “What do we know about the mechanism of action of disease-modifying treatments in MS?” J. Neurol., vol. 251(suppl. 5), pp. V/21-V/29 (2004), at pp. V/13, lines 26-30.
Fahrenholz, Falk. “Good Enzyme for Alzheimer disease ADAM,” May 18, 2004. http://www.medicalnewstoday.com/index.php?newsid=8406&nfid=rssfeeds#.
George G. Glenner, et al., “Amyloidosis of the Nervous System”,Journal of the Neurological Sciences, vol. 94, pp. 1-28 (1989).
McLendon, et al., “Cell-free assays for γ-secretase activity”,The FASEB Journal, vol. 14, pp. 2383-2386, Dec. 2000.
Feiser, Mary, “Feisers' Reagents for Organic Synthesis”,Wiley Interscience, New York, vol. 12, p. 44 (1986).
Sidney M. Hecht,Bioorganic Chemistry: Peptides and Proteins, National Library of Medicine, “Chemical Synthesis of Peptides” (Victor J. Hruby, et al.) Chapter 2, pp. 27-64.
Haass, C. and D.J. Selkoe, “Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide”, Cell Press, vol. 75, pp. 1039-1042 (1993).
J. Hann and R.A.C. Roos, “Amyloid in Central Nervous System Disease”,Clin. Neurol. Neurosurg., vol. 92-4, pp. 305-310 (1990).
Chung Susannah L.
Jubinsky James A.
Pfizer Inc.
Saeed Kamal A.
LandOfFree
Oxazole compounds for the treatment of neurodegenerative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxazole compounds for the treatment of neurodegenerative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazole compounds for the treatment of neurodegenerative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3571508